Hansa Biopharma AB Total Liabilities
Hansa Biopharma AB total liabilities. Based on the latest financial reports, Hansa Biopharma AB (HNSA) has total liabilities worth Skr1.28 Billion SEK (≈ $137.57 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Hansa Biopharma AB (HNSA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hansa Biopharma AB (2008–2024)
Total liabilities of Hansa Biopharma AB from 2008 to 2024. This chart illustrates how Hansa Biopharma AB's total liabilities have evolved over time, based on quarterly financial data. Explore Hansa Biopharma AB (HNSA) long-term investment share to see how much of total assets are deployed in long-term investments.
Hansa Biopharma AB Competitors by Total Liabilities
The table below lists competitors of Hansa Biopharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Viking Tech
TWO:3624
|
Taiwan | NT$949.58 Million |
|
Shoppers Stop Limited
NSE:SHOPERSTOP
|
India | Rs59.19 Billion |
|
Keck Seng Malaysia Bhd
KLSE:3476
|
Malaysia | RM355.23 Million |
|
Testa Residencial SOCIMI S.A.
MC:YTST
|
Spain | €1.65 Billion |
|
Wuhan Hiteck Biological Pharma Co Ltd
SHE:300683
|
China | CN¥381.30 Million |
|
Miwon Specialty Chemical Co Ltd
KO:268280
|
Korea | ₩106.74 Billion |
|
Zhejiang Runyang New Material Technology Co. Ltd.
SHE:300920
|
China | CN¥424.81 Million |
|
FinVolution Group
NYSE:FINV
|
USA | $9.58 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Hansa Biopharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HNSA current and non-current assets.
Liquidity & Leverage Metrics
Hansa Biopharma AB Total Liabilities Ratios Explained
Hansa Biopharma AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hansa Biopharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hansa Biopharma AB (2008–2024)
The table below shows the annual total liabilities of Hansa Biopharma AB from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr1.39 Billion ≈ $149.64 Million |
+17.25% |
| 2023-12-31 | Skr1.19 Billion ≈ $127.62 Million |
+9.35% |
| 2022-12-31 | Skr1.08 Billion ≈ $116.71 Million |
+324.90% |
| 2021-12-31 | Skr255.24 Million ≈ $27.47 Million |
+32.68% |
| 2020-12-31 | Skr192.37 Million ≈ $20.70 Million |
+89.68% |
| 2019-12-31 | Skr101.42 Million ≈ $10.91 Million |
+19.40% |
| 2018-12-31 | Skr84.94 Million ≈ $9.14 Million |
+70.73% |
| 2017-12-31 | Skr49.75 Million ≈ $5.35 Million |
+84.42% |
| 2016-12-31 | Skr26.98 Million ≈ $2.90 Million |
+114.77% |
| 2015-12-31 | Skr12.56 Million ≈ $1.35 Million |
+178.72% |
| 2014-12-31 | Skr4.51 Million ≈ $485.03K |
-11.57% |
| 2013-12-31 | Skr5.10 Million ≈ $548.47K |
+99.38% |
| 2012-12-31 | Skr2.56 Million ≈ $275.09K |
-58.70% |
| 2011-12-31 | Skr6.19 Million ≈ $666.02K |
+9.82% |
| 2010-12-31 | Skr5.64 Million ≈ $606.46K |
-57.39% |
| 2009-12-31 | Skr13.23 Million ≈ $1.42 Million |
+220.05% |
| 2008-12-31 | Skr4.13 Million ≈ $444.72K |
-- |
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant pa… Read more